Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease

Annachiara Cagnin, Alberto Cester, Bruno Costa, Mario Ermani, Carlo Gabelli, Giuseppe Gambina

Research output: Contribution to journalArticle

Abstract

Oral donepezil and rivastigmine are two commonly used cholinesterase inhibitors (ChEIs) used in Alzheimer’s disease (AD). The rivastigmine transdermal patch formulation has high tolerability profile, allowing patients to achieve optimal therapeutic doses and providing potential advantages over oral ChEIs. This is a 6-month, multicentre, observational efficacy and tolerability study of switching from oral ChEIs to rivastigmine patch in AD patients who failed to show benefit from previous treatment. The reasons of the switch were: (1) lack/loss of benefit from previous oral ChEI treatment; (2) tolerability problems. The primary outcome was cognitive changes measured with the mini–mental state examination (MMSE) test. Secondary outcomes were modifications of functional independence and behavioral disturbances and occurrence of adverse events (AEs) after switching. 174 patients, over 180 patients screened, entered the study (lack/loss of efficacy: 57 %, tolerability problems: 33 %, both reasons: 10 %). 6 months after switching 56 % of patients stabilized or increased the MMSE score respect to baseline. The only predictor of this outcome was the response at 3 months. In the group with lack/loss of response to oral ChEI, the decline of the MMSE score changed from −3.4 ± 2.5 points in the 6 months before switching to −0.5 ± 3.2 in the 6 months after the switch (p 

Original languageEnglish
Pages (from-to)457-463
Number of pages7
JournalNeurological Sciences
Volume36
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint

Rivastigmine
Transdermal Patch
Cholinesterase Inhibitors
Alzheimer Disease
Prospective Studies
Therapeutics

Keywords

  • Cholinesterase inhibitor drug
  • Rivastigmine patch
  • Switch among ChEIs

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology
  • Medicine(all)

Cite this

Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors : a naturalistic prospective study in Alzheimer’s disease. / Cagnin, Annachiara; Cester, Alberto; Costa, Bruno; Ermani, Mario; Gabelli, Carlo; Gambina, Giuseppe.

In: Neurological Sciences, Vol. 36, No. 3, 2015, p. 457-463.

Research output: Contribution to journalArticle

Cagnin, Annachiara ; Cester, Alberto ; Costa, Bruno ; Ermani, Mario ; Gabelli, Carlo ; Gambina, Giuseppe. / Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors : a naturalistic prospective study in Alzheimer’s disease. In: Neurological Sciences. 2015 ; Vol. 36, No. 3. pp. 457-463.
@article{00b6a1fca62f4265b02549e29980ff7b,
title = "Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer’s disease",
abstract = "Oral donepezil and rivastigmine are two commonly used cholinesterase inhibitors (ChEIs) used in Alzheimer’s disease (AD). The rivastigmine transdermal patch formulation has high tolerability profile, allowing patients to achieve optimal therapeutic doses and providing potential advantages over oral ChEIs. This is a 6-month, multicentre, observational efficacy and tolerability study of switching from oral ChEIs to rivastigmine patch in AD patients who failed to show benefit from previous treatment. The reasons of the switch were: (1) lack/loss of benefit from previous oral ChEI treatment; (2) tolerability problems. The primary outcome was cognitive changes measured with the mini–mental state examination (MMSE) test. Secondary outcomes were modifications of functional independence and behavioral disturbances and occurrence of adverse events (AEs) after switching. 174 patients, over 180 patients screened, entered the study (lack/loss of efficacy: 57 {\%}, tolerability problems: 33 {\%}, both reasons: 10 {\%}). 6 months after switching 56 {\%} of patients stabilized or increased the MMSE score respect to baseline. The only predictor of this outcome was the response at 3 months. In the group with lack/loss of response to oral ChEI, the decline of the MMSE score changed from −3.4 ± 2.5 points in the 6 months before switching to −0.5 ± 3.2 in the 6 months after the switch (p ",
keywords = "Cholinesterase inhibitor drug, Rivastigmine patch, Switch among ChEIs",
author = "Annachiara Cagnin and Alberto Cester and Bruno Costa and Mario Ermani and Carlo Gabelli and Giuseppe Gambina",
year = "2015",
doi = "10.1007/s10072-014-2002-3",
language = "English",
volume = "36",
pages = "457--463",
journal = "Neurological Sciences",
issn = "1590-1874",
publisher = "Springer-Verlag Italia s.r.l.",
number = "3",

}

TY - JOUR

T1 - Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors

T2 - a naturalistic prospective study in Alzheimer’s disease

AU - Cagnin, Annachiara

AU - Cester, Alberto

AU - Costa, Bruno

AU - Ermani, Mario

AU - Gabelli, Carlo

AU - Gambina, Giuseppe

PY - 2015

Y1 - 2015

N2 - Oral donepezil and rivastigmine are two commonly used cholinesterase inhibitors (ChEIs) used in Alzheimer’s disease (AD). The rivastigmine transdermal patch formulation has high tolerability profile, allowing patients to achieve optimal therapeutic doses and providing potential advantages over oral ChEIs. This is a 6-month, multicentre, observational efficacy and tolerability study of switching from oral ChEIs to rivastigmine patch in AD patients who failed to show benefit from previous treatment. The reasons of the switch were: (1) lack/loss of benefit from previous oral ChEI treatment; (2) tolerability problems. The primary outcome was cognitive changes measured with the mini–mental state examination (MMSE) test. Secondary outcomes were modifications of functional independence and behavioral disturbances and occurrence of adverse events (AEs) after switching. 174 patients, over 180 patients screened, entered the study (lack/loss of efficacy: 57 %, tolerability problems: 33 %, both reasons: 10 %). 6 months after switching 56 % of patients stabilized or increased the MMSE score respect to baseline. The only predictor of this outcome was the response at 3 months. In the group with lack/loss of response to oral ChEI, the decline of the MMSE score changed from −3.4 ± 2.5 points in the 6 months before switching to −0.5 ± 3.2 in the 6 months after the switch (p 

AB - Oral donepezil and rivastigmine are two commonly used cholinesterase inhibitors (ChEIs) used in Alzheimer’s disease (AD). The rivastigmine transdermal patch formulation has high tolerability profile, allowing patients to achieve optimal therapeutic doses and providing potential advantages over oral ChEIs. This is a 6-month, multicentre, observational efficacy and tolerability study of switching from oral ChEIs to rivastigmine patch in AD patients who failed to show benefit from previous treatment. The reasons of the switch were: (1) lack/loss of benefit from previous oral ChEI treatment; (2) tolerability problems. The primary outcome was cognitive changes measured with the mini–mental state examination (MMSE) test. Secondary outcomes were modifications of functional independence and behavioral disturbances and occurrence of adverse events (AEs) after switching. 174 patients, over 180 patients screened, entered the study (lack/loss of efficacy: 57 %, tolerability problems: 33 %, both reasons: 10 %). 6 months after switching 56 % of patients stabilized or increased the MMSE score respect to baseline. The only predictor of this outcome was the response at 3 months. In the group with lack/loss of response to oral ChEI, the decline of the MMSE score changed from −3.4 ± 2.5 points in the 6 months before switching to −0.5 ± 3.2 in the 6 months after the switch (p 

KW - Cholinesterase inhibitor drug

KW - Rivastigmine patch

KW - Switch among ChEIs

UR - http://www.scopus.com/inward/record.url?scp=84925483342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925483342&partnerID=8YFLogxK

U2 - 10.1007/s10072-014-2002-3

DO - 10.1007/s10072-014-2002-3

M3 - Article

C2 - 25394739

AN - SCOPUS:84925483342

VL - 36

SP - 457

EP - 463

JO - Neurological Sciences

JF - Neurological Sciences

SN - 1590-1874

IS - 3

ER -